Appendix 4E

Cochlear Limited ACN 002 618 073 Preliminary Final Report As at 30 June 2024

Results for announcement to the market

up	30 June 2023		A\$m
up			
	15%	to	2,258.2
up	15%	to	2,235.6
up	22%	to	475.0
up	19%	to	356.8
up	27%	to	386.6
up	19%	to	544.5
up	27%	to	589.8
up	24%	to	\$4.10
up	7%	to	2,121.6
			1,986.7
	up up up up up up	up 15% up 22% up 19% up 27% up 19% up 27% up 24%	up 15% to up 22% to up 19% to up 27% to up 19% to up 27% to up 24% to

per security	per security ⁴	Conduit foreign income per security ⁴	
\$2.10	\$1.68	\$0.42	
\$2.00	\$1.40	\$0.30	
\$4.10	\$3.08	\$0.72	
\$1.75	\$1.23	\$0.53	
\$1.55	\$0.54	\$0.70	
\$3.30	\$1.77	\$1.23	
etermining entitlements to the dividend 18 Septem		ber 2024	
	10 October 2024		
	\$2.00 \$4.10 \$1.75 \$1.55 \$3.30	\$2.00 \$1.40 \$4.10 \$3.08 \$1.75 \$1.23 \$1.55 \$0.54 \$3.30 \$1.77 idend 18 Septem	

No dividend reinvestment plans were in operation during or since the year-end.

Additional Appendix 4E disclosure requirements can be found in the 30 June 2024 Annual Financial Statements lodged with this document. This report is based on the 30 June 2024 Annual Financial Statements which have been audited by KPMG. The Independent Audit Report is included in the 30 June 2024 Annual Financial Statements.

² Excluding one-off and non-recurring items.

 $^{\rm 3}\,\rm Net$ tangible assets are net assets less intangible assets.

⁴ Rounded to two decimal places

¹Sales revenue is the primary revenue reporting measure used by Cochlear for the purpose of assessing revenue performance of the Consolidated Entity. It represents total revenue excluding foreign exchange contract gains/losses on hedged sales.